shinglesvaccine2019

China approves 13-valent pneumonia vaccine

pharmafile | January 2, 2020 | News story | Business Services Chinese Pharma, Pneumonia China, pneumonia, pneumonia vaccine 

China’s National Medical Products Administration (NMPA) has approved the launch of the country’s first self-developed 13-valent pneumonia vaccine to protect babies from the illness.

The pneumococcal polysaccharide conjugate vaccine is developed by the Walvax Biotechnology Ltd, and is only the second of its kind in the world. The only 13-valent pneumonia vaccine available in the global market currently is developed by Pfizer, and it was given approval to the Chinese market in 2016.

Pneumonia is a major killer of children under five and, with China having over 15 million newborns in 2018, this type of vaccine is in high demand.

Advertisement

Pneumonia kills more children than any other infectious disease, killing 800,000 under five every year according to the United Nations International Children’s Emergency Fund.

China is currently speeding up the approval process of foreign drugs to meet urgent clinical needs, but it is also supporting domestic enterprises more. It has streamlined procedures to fast-track the launch of vaccines developed in China.

Conor Kavanagh

 

Related Content

Funding to advance antimicrobial therapy for drug-resistant pneumonia

Telum Therapeutics has raised €18m in Series A financing to advance its lead antimicrobial programme …

FDA approves Merck’s Capvaxive for prevention of pneumococcal disease

Merck, known as MSD outside of the US and Canada, has announced that the US …

FDA approves Innoviva’s Xacduro for intravenous use

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, has announced that the US Food and Drug …

The Gateway to Local Adoption Series

Latest content